To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of ADHD in Euthymic Adults With Bipolar I/II Disorder

NCT01263548 | Completed

• 1 other identifier: Vyvanse-BD
• Study Type: observational
• Target: 45
• Locations: 1 country
• Sites: 1

Brief Summary

ADHD in the adult population is associated with several measures of harmful dysfunction. For example, adult ADHD is associated with high rates of separation/divorce and never-married status, lower educational attainment and occupational achievement, absenteeism, presenteeism, and job termination, as well as decreased social function. Individuals with adult ADHD are more likely than controls to have a comorbid diagnosis of bipolar disorder, alcohol and substance abuse, as well as antisocial personality disorder. Psychostimulants are the most frequently employed medications in the treatment of adult ADHD. Several psychostimulants are Health Canada and US FDA-approved for the treatment of ADHD symptoms in adulthood. Hitherto, no trial has evaluated the safety and efficacy of a psychostimulant in the treatment of ADHD symptomatology in adult individuals with bipolar disorder. Vyvanse is the first prodrug stimulant indicated for the treatment of adult (and pediatric) ADHD. Vyvanse is a therapeutically inactive molecule (i.e. prodrug). After oral ingestion, lisdexamfetamine is converted to l-lysine, a naturally occurring essential amino acid, and active d-amphetamine, which is responsible for the drug's activity. Vyvanse provides a longer duration of effect consistent throughout the day with reduced potential for risk of abuse. Vyvanse is generally well tolerated with an adverse event profile similar to other psychostimulant medications. Available evidence indicates that in most treated subjects, Vyvanse is weight-neutral and/or is associated with weight loss. Moreover, in some individuals, it is associated with improvement in both glucose and lipid homeostasis. The evaluation of safety/tolerability profiles as well as the effectiveness of lisdexamfetamine in a "real-world" population has significant translational value.

Conditions

Attention Deficit/Hyperactivity Disorder; Bipolar Disorder

Outcome Measures

Primary Outcomes (1)

• Metabolic parameters

  Weight; BMI; Waist circumference

  Screening (Week -1) to Endpoint (Week 4); Completed weekly on all 6 visits

Secondary Outcomes (6)

• ADHD-RS

  Baseline (Week 0) to Endpoint (Week 4); completed weekly on 5 visits

• CAARS

  Baseline (Week 0) to Endpoint (Week 4); completed weekly on 5 visits

• CGI-BP

  Baseline (Week 0) to Endpoint (Week 4); Completed weekly on all 6 visits

• Q-LES-Q

  Baseline (Week 0) and Endpoint (Week 4); Completed on 2 visits

• AAQoL

  Baseline (Week 0), Week 2, Endpoint (Week 4); Completed on 3 visits

Study Arms (1)

Vyvanse

This is an open-label study which means that all study participants will be taking active study medication, Vyvanse.

Drug: lisdexamfetamine dimesylate

Interventions

lisdexamfetamine dimesylate DRUG

Dosage form: Capsules; Dosage strength: 30-70mg/day, flexible dosing; Duration: 4 weeks

Also known as: Vyvanse

Vyvanse

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Individuals who have a diagnosis of Bipolar Disorder and ADHD.

You may qualify if:

• Outpatient status
• Male or female subjects between the ages of 18 to 55 years, inclusive
• Primary diagnosis of Bipolar Disorder and ADHD according to criteria in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) using the Mini International Neuropsychiatric Interview.
• Agree to use reliable method of birth control
• YMRS score \</= 12
• CGI-BP \< 6
• Able and willing to provide a written informed consent

You may not qualify if:

• Current Axis I primary psychiatric diagnosis other than Bipolar Disorder and ADHD
• Current Axis II psychiatric disorder of primary clinical focus
• Active alcohol as well as illicit or other substance abuse during the past 3 months
• Current clinically unstable medical condition.
• Inability to understand and engage in the process of informed consent.
• Inability to cooperate with study procedures.
• Presence of known allergies or hypersensitivity to lisdexamfetamine
• History of destabilization when exposed to psychostimulant medication
• Current high risk of suicide
• Current treatment with corticosteroids
• Electroconvulsive therapy in the last 1 year
• Current participation in a separate clinical research study involving an investigational drug

Sponsors & Collaborators

• University Health Network, Toronto: lead
• Shire: collaborator

Study Sites (1)

Mood Disorders Psychopharmacology Unit

Toronto, Ontario, M5T 2S8, Canada

Location

MeSH Terms

Conditions

Attention Deficit Disorder with Hyperactivity; Bipolar Disorder

Interventions

Lisdexamfetamine Dimesylate

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior Disorders; Neurodevelopmental Disorders; Mental Disorders; Bipolar and Related Disorders; Mood Disorders

Intervention Hierarchy (Ancestors)

Dextroamphetamine; Amphetamine; Amphetamines; Phenethylamines; Ethylamines; Amines; Organic Chemicals

Study Design

• Study Type: observational
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 14, 2010
• First Posted: December 20, 2010
• Study Start: October 1, 2010
• Primary Completion: January 1, 2012
• Study Completion: January 1, 2012
• Last Updated: June 1, 2012

Record last verified: 2012-05

Locations

CA (1)